MDL | MFCD10568147 |
---|---|
Molecular Weight | 281.31 |
Molecular Formula | C16H15N3O2 |
SMILES | O=C1C=C(N2CCOCC2)N=C3N1C=CC4=C3C=CC=C4 |
DNA-PK 0.28 μM (IC 50 ) |
mTOR 5.3 μM (IC 50 ) |
Compound 401 is a potent inhibitor of DNA-PK (IC 50 =0.28 μM). Compound 401 is reported to be a poor inhibitor of PI3K, ATM, and ATR in vitro, but it is active against mTOR. Compound 401 shows activity against mTOR (IC 50 =5.3 μM) but not p110α/p85α PI3K (IC 50 >100 μM). Treatment of cells with Compound 401 blocks the phosphorylation of sites modified by mTOR-Raptor and mTOR-Rictor complexes (ribosomal protein S6 kinase 1 Thr 389 and Akt Ser 473 , respectively). By contrast, there is no direct inhibition of Akt Thr 308 phosphorylation, which is dependent on PI3K. Similar effects are also observed in cells that lack DNA-PK. Compound 401 inhibits immunoprecipitated epitope-tagged mTOR or endogenous mTOR in Raptor immunoprecipitates. In both cases, inhibition of 67% or 78% is obtained at 5 μM or 10 μM Compound 401, respectively. By contrast, dose response curves show that the p110α/p85α or p110β/p85α PI3K complexes are poorly inhibited by Compound 401 at these concentrations. The proliferation of TSC1 -/- fibroblasts is inhibited in the presence of Compound 401, but TSC1 +/+ cells are resistant [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 10 mg/mL ( 35.55 mM ; ultrasonic and warming and heat to 80°C)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.5548 mL | 17.7740 mL | 35.5480 mL |
5 mM | 0.7110 mL | 3.5548 mL | 7.1096 mL |
10 mM | 0.3555 mL | 1.7774 mL | 3.5548 mL |